TirzepatideWeight Loss / GLP-1
Dual GIP/GLP-1 agonist studied for metabolic health.
- Status
- Prescription
- Developer
- Eli Lilly (LY3298176); brands Mounjaro / Zepbound
- Receptors / target
- Dual agonist of the GIP and GLP-1 receptors
- FDA-approved?
- YES
- Prescription available?
- YES
- Studied for
- type 2 diabetesobesityweight losscardiometabolic / sleep apnea
Overview
Tirzepatide (brand names Mounjaro and Zepbound) is a once-weekly, subcutaneously injected peptide that acts as a dual agonist of the GIP and GLP-1 receptors. Unlike most research peptides, it is an FDA-approved prescription drug — approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023) — supported by an extensive phase-3 human trial program (SURPASS and SURMOUNT). This profile summarizes what those trials and the FDA label report; it is a prescription medication requiring medical supervision, not a research-only compound, and nothing here is treatment guidance.
Mechanism
Tirzepatide is a single 39-amino-acid peptide engineered to activate two incretin receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual action enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. A fatty-diacid modification drives extensive albumin binding, giving a mean half-life of roughly 5 days that supports once-weekly dosing.
Clinical evidence
Human evidence is robust. In SURPASS-2 (NEJM 2021), tirzepatide was non-inferior and superior to semaglutide 1 mg for HbA1c reduction over 40 weeks in type 2 diabetes, with greater accompanying weight loss across all three doses. In SURMOUNT-1 (NEJM 2022), 72 weeks of tirzepatide produced a mean body-weight reduction of up to −20.9% at the 15 mg dose in adults with obesity, versus −3.1% for placebo. These large, randomized, placebo- and active-comparator-controlled trials formed the basis of the FDA approvals.
Safety profile
The most common adverse reactions are gastrointestinal and dose-dependent — nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain. The FDA label carries a boxed warning: tirzepatide causes thyroid C-cell tumors in rats and the human relevance is unknown, so it is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with serious hypersensitivity. Labeled warnings also include pancreatitis, hypoglycemia (especially with insulin or secretagogues), gallbladder disease and acute kidney injury from gastrointestinal fluid loss. As a prescription drug with serious labeled risks, its use requires medical supervision.
- Weeks 1–4
Dose-escalation; GI side effects (nausea, diarrhea) are most common early as appetite is suppressed and initial weight loss begins.
- Weeks 8–36
Progressive, dose-dependent weight loss and glycemic improvement across the SURPASS and SURMOUNT phase 3 trials.
- ~Week 72
SURMOUNT-1 endpoint: up to ~20.9% mean weight reduction at 15 mg. Effect is maintained with continued use and weight is largely regained if stopped.
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Large, often dramatic weight lossthe dominant reported outcome
Tirzepatide's r/Zepbound and r/Mounjaro communities are full of striking one-year transformations — 100+ lb losses and multiple dress/pant sizes, often by people who describe eating far less without the old constant hunger. Many say it worked when semaglutide or dieting alone had stalled. Self-reported, but consistent with the drug's trial data.
Reddit — r/Zepbound - Better blood sugar and diabetes controlfrequently reported by T2D users
Because it is also a diabetes drug, users with type 2 diabetes or PCOS often report their A1C dropping into the normal range (one poster went 6.4 to 5.2) alongside the weight loss, and consider it the reason they will stay on a low maintenance dose. A genuinely reported benefit beyond the scale.
Reddit — r/Mounjaro - Wider health and non-scale winsvery commonly reported
Beyond weight, people credit tirzepatide with easing joint, foot and back pain, lowering blood pressure, clearing acne, and restoring mobility and confidence — 'feeling human again.' These are subjective and bundled with the weight loss, but the theme is common and consistent across long update posts.
Reddit — r/Mounjaro - GI side effects: nausea, constipation, fatiguethe most common downside
The most frequently reported problems are gastrointestinal — nausea, 'sulfur burps,' fatigue and especially constipation, which several users warn can become serious if ignored. One widely-read cautionary post centers on severe, symptom-light constipation as a red flag people missed. Usually manageable, but the main reason people struggle or stop.
Reddit — r/Mounjaro - Loose skin after major lossasked about on nearly every transformation
As with other big-loss drugs, loose skin is the recurring caveat — commenters ask about it on almost every before/after, and posters who dropped 80-120 lb often acknowledge it as the trade-off, with some weighing skin-removal surgery. A realistic downside to the transformation stories.
Reddit — r/Zepbound - Muscle loss without protein and traininga common experienced-user caution
The community strongly stresses that rapid loss strips muscle as well as fat unless you prioritize protein and resistance training — the muscle tone on posters who lift draws immediate 'what's your routine?' questions. Framed as something you have to actively work to protect, not an automatic outcome.
Reddit — r/Zepbound - Needs ongoing dosing; regain if you stopa recurring maintenance concern
Users routinely plan to stay on a lower maintenance dose (commonly 2.5-5 mg) rather than come off, expecting appetite and weight to return otherwise — some with PCOS or diabetes say they likely won't stop at all. Reflects that it manages weight while taken rather than curing it. Anecdotal.
Reddit — r/Mounjaro
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Nausea, diarrhea, vomiting, constipation
- Decreased appetite
- Injection-site reactions
- Hypoglycemia risk with insulin/sulfonylureas
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — boxed warning; contraindicated per the FDA label.
- Known serious hypersensitivity to tirzepatide or any product component.
- History of pancreatitis warrants caution; pregnancy is generally avoided given lack of safety data and the goal of weight loss.
- Insulin or insulin secretagogues (sulfonylureas)Increased risk of hypoglycemia; the label advises considering a dose reduction of the concomitant agent.
- Oral medicationsDelayed gastric emptying can affect the absorption of co-administered oral drugs; oral contraceptive efficacy may be reduced around dose initiation/escalation.
Compare
- vs Semaglutide
Single GLP-1 agonist; tirzepatide adds GIP action
- vs Retatrutide
Investigational triple agonist building on this dual mechanism
FAQ
Is tirzepatide FDA-approved?
Yes. It is approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023). It is a prescription medication requiring medical supervision, not a research-only compound.
How does tirzepatide compare with semaglutide?
Tirzepatide is a dual GIP/GLP-1 agonist while semaglutide is a single GLP-1 agonist. In the head-to-head SURPASS-2 trial tirzepatide produced greater HbA1c reduction and weight loss than semaglutide 1 mg over 40 weeks in type 2 diabetes.
Is weight loss maintained after stopping?
No. As with other incretin agonists, the effect depends on continued use; in trial follow-up much of the lost weight is regained after discontinuation.
How is tirzepatide administered?
By once-weekly subcutaneous injection, with the dose titrated upward over time (the approved range is 2.5-15 mg). Its mean half-life of about 5 days supports the weekly schedule. Dosing decisions belong with a prescriber, not this page.
What are the most common side effects?
Gastrointestinal and dose-dependent — nausea, diarrhea, vomiting, constipation, dyspepsia and abdominal pain, plus decreased appetite. They are usually most noticeable during dose escalation. The label also warns about pancreatitis, gallbladder disease, and hypoglycemia when combined with insulin or sulfonylureas.
Does tirzepatide carry a boxed warning?
Yes. Because it caused thyroid C-cell tumors in rats (human relevance unknown), the FDA label carries a boxed warning and contraindicates it in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Related guides
GuideHow to Reconstitute Peptides: Step-by-Step Guide + BAC Water Chart (2026)GuideTirzepatide: The Complete Guide (2026)GuideRetatrutide Complete Guide: Phase 3 Results, Dosing, Side Effects & FDA StatusArticleRetatrutide vs Tirzepatide: Mechanism, Efficacy, Dosing & Cost (2026)ArticlePeptide Reconstitution Calculator: BAC Water & Syringe UnitsArticlePeptide Supply Co Review (2026): Pricing, Testing & ShippingArticleElite Research Lab Review (2026): COAs, Pricing & Is It Legit?ArticleBest Peptides for Weight Loss & Fat Loss in 2026: Cost & EvidenceArticleWhere to Buy Tirzepatide Peptide: Price & Quality Comparison (2026)Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.